Whitehawk Therapeutics, Inc.·4

Jun 15, 5:27 PM ET

Zhao Baiteng 4

Research Summary

AI-generated summary

Updated

Whitehawk (WHWK) Director Zhao Baiteng Receives Award of 38,040 Shares

What Happened

  • Director Zhao Baiteng received a grant/award covering 38,040 shares on June 12, 2026. The Form 4 lists the acquisition price as $0.00 and classifies the transaction as a derivative award (option-related). The filing was submitted on June 15, 2026.

Key Details

  • Transaction date: 2026-06-12; Form 4 filed: 2026-06-15 (timely within reporting window).
  • Reported amount: 38,040 shares; reported price: $0.00 (derivative award).
  • Vesting/conditions (footnote): Award is subject to continued service; 100% of the shares subject to the option vest on the earlier of (i) the one-year anniversary of the grant (June 12, 2027) or (ii) the day before the next annual meeting of stockholders. Grant is under the issuer’s 2021 Equity Incentive Plan.
  • Shares owned after the transaction are not provided in the excerpt of the filing.
  • No 10b5-1 plan, tax-withholding, cashless exercise, or sale was indicated in this filing.

Context

  • This is a grant of option/derivative awards, not an open-market purchase or sale. Such awards are compensation-related and subject to vesting; they do not by themselves indicate buying or selling intent by the insider.
  • For retail investors, award grants are routine executive/director compensation events. Purchases (outright buys) are often considered the stronger signal of personal conviction, while grants mainly reflect company compensation policies.